NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

UBX

Unity Biotechnology Inc

Jun 30 • 04:00PM ET

0.3841

Dollar change -0.3873
Percentage change -50.21	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE ALDX FBIO ANVS PBYI CRVS DRRX CYCN CALM SPRO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.63	Insider Own	8.92%	Shs Outstand	17.21M	Perf Week	-48.79%
Market Cap	6.61M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-8.32%	Shs Float	15.68M	Perf Month	-43.51%
Enterprise Value	12.26M	PEG	-	EPS next Q	-0.21	Inst Own	11.46%	Short Float	3.65%	Perf Quarter	-66.31%
Income	-27.50M	P/S	-	EPS this Y	42.21%	Inst Trans	-15.90%	Short Ratio	2.09	Perf Half Y	-61.59%
Sales	0.00M	P/B	-	EPS next Y	14.61%	ROA	-61.66%	Short Interest	0.57M	Perf YTD	-60.66%
Book/sh	-0.01	P/C	0.39	EPS next 5Y	40.77%	ROE	-231.27%	52W High	3.10 -87.61%	Perf Year	-72.17%
Cash/sh	0.98	P/FCF	-	EPS past 3/5Y	47.83% 39.36%	ROIC	-148.88%	52W Low	0.66 -41.80%	Perf 3Y	-93.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	26.40% 13.84%	Perf 5Y	-99.58%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	35.08%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	23.51	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.95	EPS Q/Q	-25.45%	SMA20	-48.87%	Beta	1.08	Target Price	2.33
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-53.85%	Rel Volume	8.06	Prev Close	0.77
Employees	16	LT Debt/Eq	-	Earnings	Apr 22 AMC	SMA200	-70.57%	Avg Volume	274.39K	Price	0.38
IPO	May 03, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.50% -	Trades		Volume	2,212,014	Change	-50.21%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
May-16-25	Downgrade	Mizuho	Outperform → Neutral	$6 → $1
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$8
Nov-16-23	Upgrade	Wedbush	Neutral → Outperform	$2 → $4
Jan-04-22	Upgrade	ROTH Capital	Neutral → Buy
Nov-10-21	Upgrade	Mizuho	Neutral → Buy	$5 → $7
Jun-28-21	Upgrade	Citigroup	Sell → Buy	$6
Jun-07-21	Initiated	H.C. Wainwright	Buy	$12
Feb-16-21	Downgrade	Citigroup	Neutral → Sell	$5 → $6
Aug-18-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Aug-18-20	Downgrade	Mizuho	Buy → Neutral	$33 → $4
Aug-18-20	Downgrade	Citigroup	Buy → Neutral	$31 → $5
Aug-17-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-28-20	Initiated	ROTH Capital	Buy	$35
Dec-12-19	Initiated	Cantor Fitzgerald	Overweight	$20
Mar-07-19	Initiated	Cantor Fitzgerald	Overweight	$21
Sep-07-18	Initiated	Mizuho	Buy
May-29-18	Initiated	Morgan Stanley	Overweight	$25
May-29-18	Initiated	Goldman	Neutral	$17
May-29-18	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Jun-30-25 06:32PM	Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice (GuruFocus.com) -50.21%
May-06-25 06:19AM	Bluebird pleads for deal support; Unity, Mersana lay off staff (BioPharma Dive) -14.02%
May-05-25 08:00AM	UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates (GlobeNewswire)
May-01-25 08:00AM	UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME (GlobeNewswire)
04:30PM	Loading…
Apr-22-25 04:30PM	UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-25-25 11:51AM	UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study (Zacks)
08:07AM	Unity reports topline outcomes from trial of diabetic macular oedema therapy (Clinical Trials Arena)
Mar-24-25 11:36AM	UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema (GuruFocus.com) -28.77%
07:01AM	UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema (GlobeNewswire)
Mar-23-25 04:00PM	UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025 (GlobeNewswire)
Mar-10-25 08:00AM	UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors (GlobeNewswire)
Mar-07-25 04:30PM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Jan-07-25 04:10PM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) -26.52%
Jan-06-25 08:00AM	UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) +39.06%
04:30PM	Loading…
Nov-04-24 04:30PM	UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Sep-24-24 08:00AM	UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 (GlobeNewswire)
Aug-12-24 08:00AM	UNITY Biotechnology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-24 12:00PM	UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-24 04:30PM	UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Jul-24-24 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
Jul-22-24 08:00AM	UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer (GlobeNewswire)
May-17-24 12:00PM	All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy (Zacks)
May-14-24 10:53PM	UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024 (InvestorPlace)
05:00PM	UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Apr-25-24 08:00AM	UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 10:37AM	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment (MT Newswires)
08:00AM	UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME (GlobeNewswire)
Apr-15-24 11:52AM	UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
08:00AM	Loading…
Feb-06-24 08:00AM	New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss (GlobeNewswire)
Dec-29-23 04:37PM	10 Supplements for Longevity and Antiaging: Expert Recommendations (Insider Monkey)
Dec-12-23 08:00AM	UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME (GlobeNewswire)
Nov-13-23 04:05PM	UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Nov-10-23 08:00AM	UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds (GlobeNewswire) -6.25%
Oct-17-23 05:14PM	Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks (InvestorPlace) +17.86% -12.82%
Oct-03-23 09:36PM	20 Foods Consumed By Longest Living People Every Day (Insider Monkey) -6.06%
Sep-27-23 07:00AM	UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration (GlobeNewswire)
Sep-16-23 01:02AM	Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares (GuruFocus.com)
Aug-15-23 04:51PM	20 States With The Longest Life Expectancy In America (Insider Monkey)
Aug-08-23 04:05PM	UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jun-21-23 07:00AM	UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME) (GlobeNewswire)
May-09-23 04:05PM	UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire) +15.66%
Apr-24-23 01:34PM	Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea (Benzinga) -5.19%
07:00AM	UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Apr-23-23 06:00PM	UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Mar-28-23 03:25PM	Unity (UNX) Down on Disappointing Results From Wet AMD Study (Zacks) -10.26%
Mar-27-23 01:28PM	UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug (Benzinga) -53.01%
07:30AM	UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration (GlobeNewswire)
Mar-15-23 04:05PM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-28-23 04:05PM	UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-15-23 08:00AM	UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) +10.74%
Feb-09-23 08:00AM	UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study (GlobeNewswire)
Jan-18-23 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) +7.32%
Jan-10-23 10:36AM	10 Penny Stocks That Will Make You A Millionaire (Insider Monkey) +9.48%
Nov-08-22 04:10PM	UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -14.02%
Nov-01-22 07:00AM	UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Oct-31-22 06:11PM	UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire) +12.60%
Oct-19-22 08:30AM	UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today (GlobeNewswire) -14.49%
Oct-11-22 08:00AM	UNITY Biotechnologys Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye (GlobeNewswire) -5.34%
Oct-10-22 12:00PM	All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy (Zacks)
Oct-06-22 08:00AM	UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye (GlobeNewswire)
Sep-19-22 08:00AM	UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration (GlobeNewswire)
07:00AM	The Three Best Anti-Aging Stocks to Buy in September (InvestorPlace)
Aug-31-22 08:00AM	UNITY Biotechnology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.18%
Aug-30-22 09:55AM	Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now (Zacks)
Aug-17-22 11:04PM	UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering (GlobeNewswire) -29.19% -37.11%
Aug-16-22 04:01PM	UNITY Biotechnology Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.20%
Aug-12-22 09:18AM	UNITY Biotech Shares More Than Double On Positive Drug Data For Diabetes Associated Vision Loss (Benzinga) +54.10%
07:05AM	UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
07:00AM	UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Aug-11-22 05:45PM	UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME (GlobeNewswire) -12.36%
Jul-12-22 04:00PM	UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting (GlobeNewswire) +5.93% +13.61%
Jun-29-22 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
May-26-22 08:00AM	UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors (GlobeNewswire)
May-25-22 08:00AM	UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference (GlobeNewswire)
May-10-22 04:00PM	UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -5.11%
May-05-22 08:00AM	UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases (GlobeNewswire) -6.95%
Apr-21-22 08:00AM	UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting (GlobeNewswire)
Apr-19-22 08:00AM	UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration (GlobeNewswire)
Apr-12-22 08:00AM	UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema (GlobeNewswire)
Mar-17-22 12:51PM	Investors in Unity Biotechnology (NASDAQ:UBX) from three years ago are still down 88%, even after 23% gain this past week (Simply Wall St.) +6.86%
Mar-15-22 08:00AM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates (GlobeNewswire) +6.36%
Mar-01-22 08:00AM	UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-14-22 08:00AM	UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease (GlobeNewswire) +7.10%
Feb-03-22 06:00PM	Anti-aging company Unity Biotechnology to axe half its staff, focus on eye drugs (American City Business Journals) -9.40%
04:01PM	UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs (GlobeNewswire)
Feb-02-22 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) -7.87%
Jan-25-22 05:38PM	Arbor Wealth Management, LLC Buys Wells Fargo, Activision Blizzard Inc, Amcor PLC, Sells Altice ... (GuruFocus.com)
Jan-04-22 08:00AM	UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022 (GlobeNewswire) +6.29%
Dec-22-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
Dec-20-21 08:00AM	UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of -Klotho Program (GlobeNewswire) -5.00%
Nov-10-21 12:35PM	Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases? (Benzinga) +23.35%
08:00AM	UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-09-21 07:00AM	UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease (GlobeNewswire) +8.90%
Nov-03-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire) -8.99%
Oct-06-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire) -5.64%
Oct-05-21 12:15PM	Mid-Day Market Update: Crude Oil Rises 2%; UpHealth Shares Plunge (Benzinga)
07:00AM	UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease (GlobeNewswire)
Oct-04-21 01:00AM	Hedge Funds Are Piling Into Unity Biotechnology, Inc. (UBX) (Insider Monkey) -5.76%

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nguyen Alexander Hieu	CLO and Head of Ops	Apr 02 '25	Sale	1.03	17,852	18,388	48,753	Apr 03 04:17 PM
Nguyen Alexander Hieu	Officer	Apr 02 '25	Proposed Sale	1.03	17,852	18,305		Apr 03 04:17 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Apr 02 '25	Sale	1.03	21,867	22,523	98,905	Apr 03 04:16 PM
Sullivan Lynne Marie	Officer	Apr 02 '25	Proposed Sale	1.03	21,867	22,422		Apr 03 04:16 PM
Ghosh Anirvan	Chief Executive Officer	Apr 02 '25	Sale	1.03	96,797	99,701	153,454	Apr 03 04:15 PM
Ghosh Anirvan	Officer	Apr 02 '25	Proposed Sale	1.03	96,797	99,256		Apr 03 04:15 PM
Nguyen Alexander Hieu	CLO and Head of Ops	Mar 27 '25	Sale	1.16	1,954	2,267	22,605	Mar 31 04:19 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Feb 04 '25	Sale	2.23	153	341	55,772	Feb 05 04:35 PM
Nguyen Alexander Hieu	CLO and Head of Ops	Feb 04 '25	Sale	2.23	164	366	24,559	Feb 05 04:33 PM
Ghosh Anirvan	Chief Executive Officer	Feb 04 '25	Sale	2.23	642	1,432	75,251	Feb 05 04:30 PM
Ghosh Anirvan	Chief Executive Officer	Nov 04 '24	Sale	1.29	432	557	75,893	Nov 06 04:10 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Nov 04 '24	Sale	1.29	136	175	55,925	Nov 06 04:10 PM
Nguyen Alexander Hieu	Chief Legal Officer	Nov 04 '24	Sale	1.29	149	192	24,723	Nov 06 04:10 PM
Nguyen Alexander Hieu	Chief Legal Officer	Aug 02 '24	Sale	1.53	154	236	24,872	Aug 06 05:00 PM
Ghosh Anirvan	Chief Executive Officer	Aug 02 '24	Sale	1.53	604	924	76,325	Aug 06 05:00 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Aug 02 '24	Sale	1.53	139	213	56,061	Aug 06 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UBX

Unity Biotechnology Inc

Upgrade your FINVIZ experience